About Rivpra Formulation Private Limited
Data last updated:
Rivpra Formulation Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 November 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2005PTC142755. Its GSTIN is 07AADCR2652M1Z5 (Delhi). The company holds 7 GST registrations, of which 6 are active.
The company has an authorised share capital of ₹4 Cr and a paid-up capital of ₹4 Cr. It is led by directors Vibhor Rastogi and Ram Prakash Rastogi.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 5 Manak Vihar Opp.Yojna Vihar, New Delhi, Delhi, India – 110092.
As per the financials filed for FY 2025, the company reported a revenue of ₹215.35 Cr, a decline of 7% compared to the previous year. For the same year it recorded a net profit of ₹21.11 Cr (net margin 9.8%) and EBITDA of ₹31.29 Cr (EBITDA margin 14.5%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 14% over five years.
The company has about 91 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Oteria and Rivpra Formulation. As per MCA filings, the company has open charges of ₹59 Cr and satisfied charges of ₹7.67 Cr on record. Court records list 33 cases involving the company, including 9 filed by the company and 20 filed against it; 20 cases are pending. The company has 9 deals on record (5 funding rounds, 4 secondary share transfers), with disclosed funding of ₹3.99 Cr; the latest was in March 2022. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Naprod Life Sciences Private Limited with revenue of ₹219.65 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 11 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rivpraformulation.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered Address5 Manak Vihar Opp.Yojna Vihar, New Delhi, Delhi, India – 110092
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Rivpra Formulation Private Limited
The main business activity of Rivpra Formulation is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Rivpra Formulation Private Limited FY 2024 filings available
Rivpra Formulation Private Limited reported revenue of ₹215.35 Cr (down 7% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Rivpra Formulation Private Limited
Revenue fell 7% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 14%. EBITDA rose 24% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Rivpra Formulation Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹31.29 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹21.11 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Rivpra Formulation Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 9.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Rivpra Formulation are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Rivpra Formulation Private Limited
Rivpra Formulation Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Naprod Life Sciences Private Limited | ₹219.65 Cr (FY 2025) | •••• | •••• | 1.0% | •••• | Mumbai, Maharashtra, India |
| Sava Healthcare Limited | ₹219.36 Cr (FY 2022) | •••• | •••• | 30.0% | •••• | Distt Surendranagar, Gujarat, India |
| Makson Healthcare Private Limited | ₹217.91 Cr (FY 2024) | •••• | •••• | -2.0% | •••• | Mandideep, Madhya Pradesh, India |
| Relax Pharmaceuticals Private Limited | ₹215.76 Cr (FY 2024) | •••• | •••• | 29.0% | •••• | Saharanpur, Uttar Pradesh, India |
| Brinton Pharmaceuticals Limited | ₹215.48 Cr (FY 2025) | •••• | •••• | 15.0% | •••• | Pune, Maharashtra, India |
| Rivpra Formulation Private Limited this company | ₹215.35 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | New Delhi, Delhi, India |
| Qualigens Pharma Private Limited | ₹214.78 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Khalapur, Maharashtra, India |
| Speciality Organics Pvt Ltd | ₹214.1 Cr (FY 2025) | •••• | •••• | 34.0% | •••• | Mandideep, Madhya Pradesh, India |
| Supermax Drugs & Pharmaceuticals Private Limited | ₹214.07 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Narela, Delhi, India |
| Vins Bioproducts Limited | ₹210.48 Cr (FY 2025) | •••• | •••• | 34.0% | •••• | Maheswaram, Telangana, India |
| Kilitch Drugs (India) Limited. Listed | ₹209.48 Cr (FY 2025) | •••• | •••• | 32.0% | •••• | Thane, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Rivpra Formulation by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Rivpra Formulation Private Limited
Rivpra Formulation Private Limited is audited by Jitender R Deo & Company for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Jitender R Deo & Company | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Rivpra Formulation Private Limited
Rivpra Formulation has 2 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vibhor Rastogi | Director | 21 Nov 2005 | 20 Years 10 Months | Current |
| Ram Prakash Rastogi | Director | 28 Mar 2015 | 11 Years 6 Months | Current |
Ownership and Shareholding of Rivpra Formulation Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Rivpra Formulation Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Apr 2024 | Hdfc Bank Limited | ₹18 Cr | Open |
| 03 May 2023 | Others | ₹5 Cr | Open |
| 13 Mar 2023 | Others | ₹5 Cr | Open |
| 22 Mar 2016 | Hdfc Bank Limited | ₹31 Cr | Open |
| 09 May 2019 | Others | ₹8 Lakh | Satisfied |
Total charge records: 8 View all charges
Deals & Funding of Rivpra Formulation Private Limited
Rivpra Formulation Private Limited has 9 deals on record (5 funding rounds, 4 secondary share transfers), with disclosed funding of ₹3.99 Cr; the latest was in March 2022.
Deals on record (5 of 9)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Aug 2019 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| May 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Rajesh Kumar Rastogi HUF, an individual |
| Mar 2017 | Funding round | ₹25 Lakh | Investors: 2 individuals |
| May 2015 | Funding round | ₹1.75 Cr | Investors: 3 individuals |
Full deal history
All 9 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Rivpra Formulation Private Limited
Rivpra Formulation Private Limited has 33 court cases on record: 9 filed by Rivpra Formulation, 20 filed against it, 4 where it is another party. 20 cases are pending and 13 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 25 | 19 | 15 |
| High courts | 8 | 1 | 5 |
Cases on record (5 of 33)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, East, Delhi | Criminal case | Filed by the company against Taru Pharma Private Limited | Disposed |
| District court, Ghaziabad, Uttar Pradesh | Criminal case | Filed against the company by State Government | Pending |
| District court, Kanniyakumari, Tamil Nadu | Criminal miscellaneous application | Filed against the company by an individual | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Interim or miscellaneous application | Filed against the company by Union of India | Pending |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by an individual | Pending |
Full case history
All 33 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Rivpra Formulation Private Limited
Rivpra Formulation Private Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 11 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 11)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Biogenetic Healthcare | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Indo Pack Limited | •••• | •••• | •••• |
| S.K.Industries | •••• | •••• | •••• |
| Rakshit Pharmaceuticals Limited | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 1 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Rivpra Formulation Private Limited
Rivpra Formulation operates two associated brands: Oteria and Rivpra Formulation. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Skincare products aligned with skin's natural rhythms for effective daily care. | oteria.com | |
| Manufacturer of generic tablets, capsules, and liquid | rivpraformulation.com |
Employees and EPFO Compliance at Rivpra Formulation Private Limited
Rivpra Formulation Private Limited has a workforce of 91 employees as of Mar 21, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Rivpra Formulation Private Limited
Rivpra Formulation Private Limited has 6 board changes on record since 2005: 3 appointments and 3 cessations. The latest: Anand Kumar Singh was appointed as Manager on 11 Jan 2024.
10 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Rivpra Formulation Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Rivpra Formulation Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Rivpra Formulation Private Limited
Rivpra Formulation has 7 GST registrations: 6 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AADCR2652M1Z5 | Delhi | Active | 21 Jul 2017 |
| 05AADCR2652M1Z9 | Uttarakhand | Active | 01 Jul 2017 |
| 09AADCR2652M1Z1 | Uttar Pradesh | Active | 09 Jul 2018 |
| 23AADCR2652M1ZB | Madhya Pradesh | Active | 10 May 2022 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Rivpra Formulation Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rivpra Formulation Private Limited
Rivpra Formulation is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 21 November 2005 (21+ years old) and is registered under CIN U24232DL2005PTC142755.
Rivpra Formulation reported revenue of ₹215.35 Cr for FY 2025 (down 7% YoY).
Rivpra Formulation has 2 current directors:
- Vibhor Rastogi - Director
- Ram Prakash Rastogi - Director
Rivpra Formulation reported a net profit of ₹21.11 Cr (net margin 9.8%) and EBITDA of ₹31.29 Cr (EBITDA margin 14.5%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Rivpra Formulation is 7% over three years and 14% over five years. In the latest year (FY 2025) revenue fell 7%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Rivpra Formulation is 07AADCR2652M1Z5, registered in Delhi. The company has 7 GST registrations in all, of which 6 are active and 1 is cancelled or inactive. Other active GSTINs include 05AADCR2652M1Z9 (Uttarakhand), 09AADCR2652M1Z1 (Uttar Pradesh), 23AADCR2652M1ZB (Madhya Pradesh).
The CIN (Corporate Identification Number) of Rivpra Formulation is U24232DL2005PTC142755. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Rivpra Formulation has 33 court cases on record: 9 filed by the company and 20 filed against it. 20 are pending. Most are in the district courts.
Rivpra Formulation was incorporated on 21 November 2005, making it 21+ years old. It is registered with the Registrar of Companies, Delhi.
Rivpra Formulation has 9 deals on record (5 funding rounds, 4 secondary share transfers), with disclosed funding of ₹3.99 Cr; the latest was in March 2022.
The peers of Rivpra Formulation by revenue are Naprod Life Sciences Private Limited, Sava Healthcare Limited, Makson Healthcare Private Limited, Relax Pharmaceuticals Private Limited, Brinton Pharmaceuticals Limited and 5 more, all in the Pharma industry (Formulations).
Anand Kumar Singh was appointed as Manager on 11 Jan 2024. Neelima Rastogi ceased to be Director on 31 May 2018. Rajesh Kumar Rastogi ceased to be Director on 31 May 2018. Rivpra Formulation has 6 board changes on record in total.